A total paradigm shift in treating CHF. We're talking 2 Billion dollar market potential in less than a year after approval, and a marketplace worth close to 10 Billion dollars.
1+ billion dollar market cap and at least 2 years away from approval, means more dilution over the coming year. Seems over priced right now. No sign of revenue for 3 years. Comments?
It seems they are beginning to use Melafind in their Melanoma clinic. Doctors are saying the product is well designed and provides excellent clinical data for cataloging and mole assessment. If some of the best specialists in the world are using this system, there must be something good here. Market Cap seems very cheap for such a huge market with no competition.
I don't think so. This is huge new for the ALS community and is sure to make national news this evening.
Bottom line, this has further retracement in the charts. I would hold out for $18 range before opening a position.
Biotech is showing signs of weakness.